Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer

被引:68
|
作者
Zaravinos, Apostolos [1 ,2 ]
Roufas, Constantinos [1 ,3 ]
Nagara, Majdi [4 ]
de Lucas Moreno, Beatriz [1 ,5 ]
Oblovatskaya, Maria [1 ]
Efstathiades, Christodoulos [2 ,3 ]
Dimopoulos, Christos [2 ,3 ]
Ayiomamitis, Georgios D. [6 ]
机构
[1] European Univ Cyprus, Sch Sci, Dept Life Sci, CY-1516 Nicosia, Cyprus
[2] Ctr Risk & Decis Sci CERIDES, CY-2404 Nicosia, Cyprus
[3] European Univ Cyprus, Dept Comp Sci & Engn, CY-1516 Nicosia, Cyprus
[4] Aix Marseille Univ, Fac Med, INSERM, UMR S 1251,MMG, Marseille, France
[5] European Univ Madrid, Ctr Res Hlth & Life Sci, Madrid 28670, Spain
[6] Tzane Gen Hosp, Surg Dept 1, Piraeus 18536, Greece
关键词
Colorectal cancer; Cytolytic activity; Classically defined neoepitopes; Alternatively defined neoepitopes; Mutation burden; Immune checkpoints; Cancer drivers; CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; ANTI-PD-L1; ANTIBODY; GENOMIC INSTABILITY; CLINICAL IMPACT; SOLID TUMORS; COLON; SURVIVAL;
D O I
10.1186/s13046-019-1372-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMicrosatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC's biology, including neoepitope burden.MethodsWe used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR.ResultsCRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/-II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients' overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts.ConclusionsOverall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
    Apostolos Zaravinos
    Constantinos Roufas
    Majdi Nagara
    Beatriz de Lucas Moreno
    Maria Oblovatskaya
    Christodoulos Efstathiades
    Christos Dimopoulos
    Georgios D. Ayiomamitis
    Journal of Experimental & Clinical Cancer Research, 38
  • [2] Immune cytolytic activity is correlated with distinct mutational events in colorectal cancer
    Zaravinos, Apostolos
    Roufas, Konstantinos
    Efstathiades, Christodoulos
    Dimopoulos, Christos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S25 - S25
  • [3] Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis
    Roufas, Constantinos
    Georgakopoulos-Soares, Ilias
    Zaravinos, Apostolos
    NAR CANCER, 2021, 3 (01):
  • [4] Immune checkpoints and immunotherapy for colorectal cancer
    Singh, Preet Paul
    Sharma, Piyush K.
    Krishnan, Gayathri
    Lockhart, A. Craig
    GASTROENTEROLOGY REPORT, 2015, 3 (04): : 289 - 297
  • [5] Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer
    Malla, Midhun
    Deshmukh, Sachin Kumar
    Wu, Sharon
    Samec, Timothy
    Olevian, Dane C.
    El Naili, Reima
    El-Rayes, Bassel
    Xiu, Joanne
    Farrell, Alex
    Lenz, Heinz-Josef
    Lou, Emil
    Goel, Sanjay
    Spetzler, David
    Goldberg, Richard M.
    Hazlehurst, Lori
    CANCER GENE THERAPY, 2024, 31 (10) : 1547 - 1558
  • [6] MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer
    Huang, Jiahao
    Liu, Haizhou
    Zhao, Yang
    Luo, Tao
    Liu, Jungang
    Liu, Junjie
    Pan, Xiaoyan
    Tang, Weizhong
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [7] Immune Checkpoints as a Target for Colorectal Cancer Treatment
    Passardi, Alessandro
    Canale, Matteo
    Valgiusti, Martina
    Ulivi, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (06)
  • [8] Advances of immune checkpoints in colorectal cancer treatment
    Jiao, Qinlian
    Ren, Yidan
    Gabrie, Abakundana Nsenga Ariston
    Wang, Qin
    Wang, Yuli
    Du, Lutao
    Liu, Xiaoyan
    Wang, Chuanxin
    Wang, Yun-shan
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [9] Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression
    Van den Eynde, M.
    Mlecnik, B.
    Bindea, G.
    Fredriksen, T.
    Lafontaine, L.
    Haicheur, N.
    Marliot, F.
    Debetancourt, D.
    Jouret-Mourin, A.
    Sempoux, C.
    Gigot, J. F.
    Hubert, C.
    Kartheuser, A.
    Remue, C.
    Leonard, D.
    Carrasco, J.
    Humblet, Y.
    Pages, F.
    Machiels, J. P.
    Galon, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S385 - S385
  • [10] MSI and Tumor Mutational Burden in Colorectal Cancer
    Kuetting, Fabian
    Bludau, Marc
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2019, 25 (09): : 829 - 830